Search Results
4 Perspectives on How Nonprofits Help
If you want to change the world, there’s more than one way to do it. You could start in your community, helping friends and neighbors. You could also turn to a nonprofit organization—as a volunteer, donor, advocate, or even by joining the staff—to widen your impact.
We know a lot of changemakers at The Leukemia & Lymphoma Society (LLS). Passionate, amazing people who work hard to help us make life better for blood cancer patients, survivors, and their families. They know that we can make the most progress toward a world without blood cancer together.
Cancer Researcher Runs Alaska Half Marathon to Raise Funds for Lifesaving Treatments
Not only has Irene Ghobrial, M.D. dedicated her professional life to finding lifesaving treatments for cancer, but over the past few months she has dedicated her leisure time to training for a half marathon in Alaska, to raise funds for cancer research. Ghobrial has trained with The Leukemia & Lymphoma Society’s (LLS) Team In Training (TNT), the non-profit’s endurance training program.
Bringing the Patient Voice into Drug Development
Wanting to make sure the patient voice is heard when it comes to the development of new therapies, The Leukemia & Lymphoma Society (LLS) recently brought a delegation to Washington D.C. to share personal experiences with the U.S. Food & Drug Administration (FDA). Plans for a research study to learn what patients and caregivers are looking for in new treatments were also presented.
Dispelling Misunderstandings About Clinical Trials
As a clinical trials specialist for The Leukemia & Lymphoma Society, I guide blood cancer patients and their families through the process of determining whether a clinical trial might be right for them. I try to clarify any misconceptions people have about what is involved so they will be in a much better place to make a decision. This blog addresses some of the most common misunderstandings. Considering a clinical trial for treatment of a blood cancer?
A Phase I/II Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients with Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
SIRPα+ macrophages mediate resistance to lenalidomide in B-cell lymphoma, limiting the activity of immunotherapy for these patients. Therefore, we propose a phase I/II study, investigating the safety and efficacy of ALX148, a novel fusion protein of the SIRPα binding domain, in combination with rituximab and lenalidomide in patients with B-cell lymphoma. We hypothesize that this combination will be safe and effective, providing a chemotherapy-free option for these patients.
Volunteers: The Engine Powering LLS’s Mission
I was always aware that volunteers with The Leukemia & Lymphoma Society (LLS) drive impact for blood cancer patients and families. But it wasn’t until Thanksgiving Day 2007 that I discovered the full force of their power. My wife, Holly, had recently been diagnosed with follicular lymphoma and our family was still reeling from the news. She was feeling quite ill, and we were exhausted with worry and trying to keep life as normal as possible for our two young children.
Bexarotene
Bexarotene is FDA approved to treat people who have skin problems arising from cutaneous T-cell lymphoma (CTCL) in patients who are refractory for at least one prior systemic therapy. It may be used after other drugs have been tried and the tumor is still a problem.
DEVELOPING RELATIONSHIPS ON CAPITOL HILL
As the voice for all blood cancer patients, The Leukemia & Lymphoma Society (LLS) establishes and grows meaningful relationships with policymakers
The Leukemia & Lymphoma Society is committed to removing barriers to care for blood cancer patients, and works with federal and state legislators to advocate for policies to ensure patients have access to quality, affordable care and treatments they need.
Here’s an inside look at how we cultivate these key connections:
#ASH16 (Blog 1): Is the Best Yet to Come in Immunotherapy?
This is the first of a series of blogs covering the 58th ASH Annual Meeting and Exposition in San Diego (#ASH16) conference over the next few days. Check back for more news from the meeting.
The Bright Light (Actually Two!) at the End of the Tunnel
I was 28, married for two years, and my husband and I had just celebrated our one-year anniversary at my business, Gigi’s Cupcakes. We were happy and healthy and ready to start thinking about having a family. Life was perfect!
Panelists Discuss the AML Patient Experience
What is AML? What research is underway? And what resources are available to patients?
The Leukemia & Lymphoma Society recently joined up with Patient Power and the MDS Alliance to host an AML Awareness Day and answer those questions.
The April 21 webcast was moderated by Carol Preston, host of Patient Power, an online portal offering cancer information for both patients and professionals. Preston is also a chronic lymphocytic leukemia (CLL) survivor.
Interferon alfa-2b
Interferons are substances naturally produced by cells in the body to help fight infections and tumors. They may also be synthetic versions of these substances.
Interferon alfa-2b is FDA approved to treat people who have hairy cell leukemia, polycythemia vera and aggressive follicular non-Hodgkin lymphoma.
Procarbazine
Procarbazine is FDA approved with other anticancer drugs for the treatment of stage III and IV Hodgkin lymphoma. Procarbazine is used as part of the MOPP (mechlorethamine, Oncovin® [vincristine], procarbazine, prednisone) regimen. This medicine may cause a temporary loss of hair in some people. After treatment with procarbazine has ended, normal hair growth should return.